INOmax® EVOLVE DS™ 2023 WINNER - Human Factors and Ergonomics Society, UCD Award

Through moments of calm and crisis

The INOmax Total Care® offering has been there

Learn more
INOmax Total Care Shield Logo

The INOmax Total Care offering

The INOmax Total Care offering remains the market leader* for delivery systems, service, support, and INOmax® (nitric oxide) gas, for inhalation, for term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension.1,2

*Based on December 2022 market share data.

Delivery Systems

Designed to help mitigate inhaled nitric oxide disruptions3-6

Service & Support

24/7/365 service, device education, training, and support

Drug

The first selective pulmonary vasodilator with well-established cylinder-based delivery1,7,8

Our Legacy

Decades of being by your side in the NICU

*Data from 2020 to 2022.

See how the INOmax Total Care team can help support your institution

Contact a representative

INDICATION

INOmax is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

IMPORTANT SAFETY INFORMATION

  • INOmax® (nitric oxide) gas, for inhalation, is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.
  • Abrupt discontinuation of INOmax may lead to increasing pulmonary artery pressure and worsening oxygenation.
  • Methemoglobinemia and NO2 levels are dose dependent. Nitric oxide donor compounds may have an additive effect with INOmax on the risk of developing methemoglobinemia. Nitrogen dioxide may cause airway inflammation and damage to lung tissues.
  • In patients with pre-existing left ventricular dysfunction, INOmax may increase pulmonary capillary wedge pressure leading to pulmonary edema.
  • Monitor for PaO2, inspired NO2, and methemoglobin during INOmax administration.
  • INOmax must be administered using a calibrated FDA-cleared Nitric Oxide Delivery System.

Please see Full Prescribing Information.

References: 1. INOmax. Package insert. Mallinckrodt Pharmaceuticals. 2. Data on File – Ref-06557. Mallinckrodt Pharmaceuticals. 3. INOmax DSIR® Plus Operation Manual. Hampton, NJ: INO Therapeutics LLC; 2014. 4. INOmax DSIR® Plus MRI Operation Manual. Hampton, NJ: INO Therapeutics LLC; 2015. 5. INOmax EVOLVE™ DS Operation Manual. Madison, WI: Mallinckrodt Pharmaceuticals; 2024. 6. Data on File – Ref-05507. Mallinckrodt Pharmaceuticals. 7. Ichinose F, Roberts JD Jr, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation. 2004;109(25):3106-3111. doi:10.1161/01.CIR.0000134595.80170.62 8. Environmental assessment and/or FONSI: NDA 20845. Center for Drug Evaluation and Research. Published February 21, 1997. 9. Data on File – Ref-06556. Mallinckrodt Pharmaceuticals.

Live help is available 24/7/365

Call 877-566-9466

Quick Links

INOmax DSIR® Plus Virtual Training Simulator Resource Library FLEXtraNet® Log-in INOmax DSIR® Plus Operation Manual INOmax DSIR® Plus MRI Operation Manual

Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners.

This website may identify third-party organizations and provide links to third-party websites or other third-party information (third-party content). The third-party content is meant for informational purposes only, is not endorsed by or under the control of Mallinckrodt, and is not meant to replace a physician’s medical advice. Mallinckrodt has no responsibility or liability for and makes no representations or warranties whatsoever about any third-party content. All trademarks, service marks, and logos appearing on this website are the property of their respective owners. Any rights not expressly granted herein are reserved.

© 2024 Mallinckrodt. All rights reserved. US-2400124 03/24

By viewing this site you agree to our Terms of Use. The product information provided in this site is intended only for residents of the United States. The product discussed herein may have different product labeling in different countries.

INDICATION

INOmax is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

INDICATION

INOmax is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

IMPORTANT SAFETY INFORMATION

  • INOmax® (nitric oxide) gas, for inhalation, is contraindicated in the treatment of neonates dependent on right-to-left shunting of blood.
  • Abrupt discontinuation of INOmax may lead to increasing pulmonary artery pressure and worsening oxygenation.
  • Methemoglobinemia and NO2 levels are dose dependent. Nitric oxide donor compounds may have an additive effect with INOmax on the risk of developing methemoglobinemia. Nitrogen dioxide may cause airway inflammation and damage to lung tissues.
  • In patients with pre-existing left ventricular dysfunction, INOmax may increase pulmonary capillary wedge pressure leading to pulmonary edema.
  • Monitor for PaO2, inspired NO2, and methemoglobin during INOmax administration.
  • INOmax must be administered using a calibrated FDA-cleared Nitric Oxide Delivery System.

Please see Full Prescribing Information.